NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature

M. Talal F. Al-Mayhani, Richard Grenfell, Masashi Narita, Sara Piccirillo, Emma Kenney-Herbert, James W. Fawcett, Peter V. Collins, Koichi Ichimura, Colin Watts

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most common type of primary brain tumor and a highly malignant and heterogeneous cancer. Current conventional therapies fail to eradicate or curb GBM cell growth. Hence, exploring the cellular and molecular basis of GBM cell growth is vital to develop novel therapeutic approaches. Neuroglia (NG)-2 is a transmembrane proteoglycan expressed by NG21 progenitors and is strongly linked to cell proliferation in the normal brain. By using NG2 as a biomarker we identify a GBM cell population (GBM NG21 cells) with robust proliferative, clonogenic, and tumorigenic capacity. We show that a significant proportion (mean 83%) of cells proliferating in the tumor mass express NG2 and that over 50% of GBM NG21 cells are proliferating. Compared with the GBM NG22 cells from the same tumor, the GBM of NG21 cells overexpress genes associated with aggressive tumorigenicity, including overexpression of Mitosis and Cell Cycling Module genes (e.g., MELK, CDC, MCM, E2F), which have been previously shown to correlate with poor survival in GBM. We also show that the coexpression pattern of NG2 with other glial progenitor markers in GBM does not recapitulate that described in the normal brain. The expression of NG2 by such an aggressive and actively cycling GBM population combined with its location on the cell surface identifies this cell population as a potential therapeutic target in a subset of patients with GBM.

Original languageEnglish (US)
Pages (from-to)830-845
Number of pages16
JournalNeuro-Oncology
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

Glioblastoma
Population
Neuroglia
Neoplasms
Gene Regulatory Networks
Brain
Proteoglycans
Centers for Disease Control and Prevention (U.S.)
Growth
Mitosis
Brain Neoplasms
Therapeutics
Biomarkers
Cell Proliferation

Keywords

  • Glioblastoma
  • Molecular signature
  • NG2
  • Progenitor
  • Proliferation

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Al-Mayhani, M. T. F., Grenfell, R., Narita, M., Piccirillo, S., Kenney-Herbert, E., Fawcett, J. W., ... Watts, C. (2011). NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro-Oncology, 13(8), 830-845. https://doi.org/10.1093/neuonc/nor088

NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. / Al-Mayhani, M. Talal F.; Grenfell, Richard; Narita, Masashi; Piccirillo, Sara; Kenney-Herbert, Emma; Fawcett, James W.; Collins, Peter V.; Ichimura, Koichi; Watts, Colin.

In: Neuro-Oncology, Vol. 13, No. 8, 01.08.2011, p. 830-845.

Research output: Contribution to journalArticle

Al-Mayhani, MTF, Grenfell, R, Narita, M, Piccirillo, S, Kenney-Herbert, E, Fawcett, JW, Collins, PV, Ichimura, K & Watts, C 2011, 'NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature', Neuro-Oncology, vol. 13, no. 8, pp. 830-845. https://doi.org/10.1093/neuonc/nor088
Al-Mayhani MTF, Grenfell R, Narita M, Piccirillo S, Kenney-Herbert E, Fawcett JW et al. NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro-Oncology. 2011 Aug 1;13(8):830-845. https://doi.org/10.1093/neuonc/nor088
Al-Mayhani, M. Talal F. ; Grenfell, Richard ; Narita, Masashi ; Piccirillo, Sara ; Kenney-Herbert, Emma ; Fawcett, James W. ; Collins, Peter V. ; Ichimura, Koichi ; Watts, Colin. / NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. In: Neuro-Oncology. 2011 ; Vol. 13, No. 8. pp. 830-845.
@article{609838fcf9b54116b234f522315d3cb7,
title = "NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature",
abstract = "Glioblastoma multiforme (GBM) is the most common type of primary brain tumor and a highly malignant and heterogeneous cancer. Current conventional therapies fail to eradicate or curb GBM cell growth. Hence, exploring the cellular and molecular basis of GBM cell growth is vital to develop novel therapeutic approaches. Neuroglia (NG)-2 is a transmembrane proteoglycan expressed by NG21 progenitors and is strongly linked to cell proliferation in the normal brain. By using NG2 as a biomarker we identify a GBM cell population (GBM NG21 cells) with robust proliferative, clonogenic, and tumorigenic capacity. We show that a significant proportion (mean 83{\%}) of cells proliferating in the tumor mass express NG2 and that over 50{\%} of GBM NG21 cells are proliferating. Compared with the GBM NG22 cells from the same tumor, the GBM of NG21 cells overexpress genes associated with aggressive tumorigenicity, including overexpression of Mitosis and Cell Cycling Module genes (e.g., MELK, CDC, MCM, E2F), which have been previously shown to correlate with poor survival in GBM. We also show that the coexpression pattern of NG2 with other glial progenitor markers in GBM does not recapitulate that described in the normal brain. The expression of NG2 by such an aggressive and actively cycling GBM population combined with its location on the cell surface identifies this cell population as a potential therapeutic target in a subset of patients with GBM.",
keywords = "Glioblastoma, Molecular signature, NG2, Progenitor, Proliferation",
author = "Al-Mayhani, {M. Talal F.} and Richard Grenfell and Masashi Narita and Sara Piccirillo and Emma Kenney-Herbert and Fawcett, {James W.} and Collins, {Peter V.} and Koichi Ichimura and Colin Watts",
year = "2011",
month = "8",
day = "1",
doi = "10.1093/neuonc/nor088",
language = "English (US)",
volume = "13",
pages = "830--845",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature

AU - Al-Mayhani, M. Talal F.

AU - Grenfell, Richard

AU - Narita, Masashi

AU - Piccirillo, Sara

AU - Kenney-Herbert, Emma

AU - Fawcett, James W.

AU - Collins, Peter V.

AU - Ichimura, Koichi

AU - Watts, Colin

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Glioblastoma multiforme (GBM) is the most common type of primary brain tumor and a highly malignant and heterogeneous cancer. Current conventional therapies fail to eradicate or curb GBM cell growth. Hence, exploring the cellular and molecular basis of GBM cell growth is vital to develop novel therapeutic approaches. Neuroglia (NG)-2 is a transmembrane proteoglycan expressed by NG21 progenitors and is strongly linked to cell proliferation in the normal brain. By using NG2 as a biomarker we identify a GBM cell population (GBM NG21 cells) with robust proliferative, clonogenic, and tumorigenic capacity. We show that a significant proportion (mean 83%) of cells proliferating in the tumor mass express NG2 and that over 50% of GBM NG21 cells are proliferating. Compared with the GBM NG22 cells from the same tumor, the GBM of NG21 cells overexpress genes associated with aggressive tumorigenicity, including overexpression of Mitosis and Cell Cycling Module genes (e.g., MELK, CDC, MCM, E2F), which have been previously shown to correlate with poor survival in GBM. We also show that the coexpression pattern of NG2 with other glial progenitor markers in GBM does not recapitulate that described in the normal brain. The expression of NG2 by such an aggressive and actively cycling GBM population combined with its location on the cell surface identifies this cell population as a potential therapeutic target in a subset of patients with GBM.

AB - Glioblastoma multiforme (GBM) is the most common type of primary brain tumor and a highly malignant and heterogeneous cancer. Current conventional therapies fail to eradicate or curb GBM cell growth. Hence, exploring the cellular and molecular basis of GBM cell growth is vital to develop novel therapeutic approaches. Neuroglia (NG)-2 is a transmembrane proteoglycan expressed by NG21 progenitors and is strongly linked to cell proliferation in the normal brain. By using NG2 as a biomarker we identify a GBM cell population (GBM NG21 cells) with robust proliferative, clonogenic, and tumorigenic capacity. We show that a significant proportion (mean 83%) of cells proliferating in the tumor mass express NG2 and that over 50% of GBM NG21 cells are proliferating. Compared with the GBM NG22 cells from the same tumor, the GBM of NG21 cells overexpress genes associated with aggressive tumorigenicity, including overexpression of Mitosis and Cell Cycling Module genes (e.g., MELK, CDC, MCM, E2F), which have been previously shown to correlate with poor survival in GBM. We also show that the coexpression pattern of NG2 with other glial progenitor markers in GBM does not recapitulate that described in the normal brain. The expression of NG2 by such an aggressive and actively cycling GBM population combined with its location on the cell surface identifies this cell population as a potential therapeutic target in a subset of patients with GBM.

KW - Glioblastoma

KW - Molecular signature

KW - NG2

KW - Progenitor

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=80052740275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052740275&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nor088

DO - 10.1093/neuonc/nor088

M3 - Article

C2 - 21798846

AN - SCOPUS:80052740275

VL - 13

SP - 830

EP - 845

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 8

ER -